News about "Mankind Pharma "

Mankind Pharma In-Licenses Two Insulin Analogues from China for Indian Market

Mankind Pharma has signed an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for Insulin Degludec and Insulin Degludec plus Aspart combination in India, strengthening its injectable diabetes portfolio.

Mankind Pharma | 20/08/2026 | By News Bureau

Mankind Pharma Partners with Denovo Sciences to Accelerate AI-Driven Drug Discovery

The collaboration between Mankind Pharma and Denovo Sciences launches AI-powered drug discovery to accelerate research timelines and improve lead candidate quality.

Mankind Pharma | 02/07/2026 | By News Bureau

Mankind Pharma Acquires Rivotril Brand for India, Reinforcing Focus on Chronic CNS Therapies

Mankind Pharma Limited today announced that it has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions.

Mankind Pharma | 19/03/2026 | By Darshana |  215

Mankind Pharma Urges Greater Kidney Health Awareness as CKD Burden Rises

On World Kidney Day, Mankind Pharma highlights rising cases of Chronic Kidney Disease in India and stresses early screening, lifestyle changes and awareness to prevent late-stage diagnosis.

Mankind Pharma | 12/03/2026 | By News Bureau |  181

Mankind Pharma Sees Margin Expansion, Chronic Segment Gains in Q3FY26

Mankind Pharma announced its consolidated financial results for the third quarter and nine months ended December 31, 2025, reporting steady growth driven by improved performance in its domestic pharmaceutical business and consolidation of its BSV portfolio.

Mankind Pharma | 04/02/2026 | By Darshana |  206

Actimed Therapeutics Announces Licensing Agreement with Mankind Pharma

Actimed Therapeutics has entered into an exclusive licensing agreement with Mankind Pharma for S-pindolol, its novel therapy in development for cancer cachexia. The partnership marks a step toward delivering the first globally approved treatment for this debilitating condition to patients across India and South Asia.

Mankind Pharma | 21/11/2025 | By Dineshwori |  168

Mankind Pharma Q2 Net Profit Falls 21 Percent to INR 520 Crore

Mankind Pharma reported a 21 percent year-on-year decline in consolidated net profit for the quarter ended September 30, 2025, with profit falling to approximately INR 520 crore from INR 661 crore in the same period last year.

Mankind Pharma | 07/11/2025 | By Darshana |  234

Mankind Pharma Partners with OpenAI to Embed AI Across Operations

Mankind Pharma has announced a strategic collaboration with OpenAI, aimed at integrating artificial intelligence across its entire value chain. The move marks one of the first times an Indian pharmaceutical company has committed to fully embedding advanced AI into its core operations.

Mankind Pharma | 18/09/2025 | By Darshana |  605

Mankind Pharma Gets CDSCO Nod to Begin Phase 1 Trials of Novel Autoimmune Drug Candidate MKP11093

Mankind Pharma Ltd., India’s 4th largest pharmaceutical company, today announced that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate a Phase 1 clinical trial of MKP11093, a novel, orally administered Janus kinase-1 (JAK-1) inhibitor.

Mankind Pharma | 08/09/2025 | By Darshana |  196

Mankind Pharma Expands into Sri Lanka With New Subsidiary

Mankind Pharma has incorporated a wholly owned subsidiary, Mankind Pharma Lanka (Private) Ltd., in Sri Lanka as part of its international expansion strategy.

Mankind Pharma | 26/07/2025 | By Dineshwori |  390